The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Improving transplantation rates by increasing CR in AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses ways in which transplantation rates in acute myeloid leukemia (AML) can be improved. Increasing the proportion of patients in complete remission (CR), with adequate blood count recovery, is crucial to improve transplantation rates. Ongoing efforts are focused on suppressing measurable residual disease (MRD) before transplantation. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting/advisory: Rigel, Remix, Astellas, Gilead, Pfizer, Genetech, AstraZeneca, Syndax, Takeda, Schrodinger, Servier, Abbvie, BMS, Prelude; Clinical trial support: BMS, Servier, Abbvie.
